FUJIFILM Collaborated with Argenx to Manufacture Efgartigimod for the Treatment of Severe Autoimmune Diseases
Shots:
- The companies collaborated to manufacture efgartigimod targeting neonatal Fc receptor for sev. autoimmune disease. FUJIFILM will manufacture efgartigimod drug substance at its large-scale biomanufacturing facility in Hillerd, Denmark
- FUJIFILM provides expertise and technologies to bring therapy to patients. The collaboration offers the ability for new programs and provides a well-established and strong ecosystem for large-scale production of therapeutic Abs for commercial use
- Efgartigimod has been approved in the US & EU for gMG who are AChR Ab & in Japan for gMG who do not have a sufficient response to steroids or non-steroidal immunosuppressive therapies. The therapy is also being studied for other sev. autoimmune diseases
Ref: GlobeNewswire | Image: FUJIFILM
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
